Clinical trial Recruiting at 1 site Observational Ages 18 to 75

Evaluating 18F-FAPI-04 PET Imaging for Breast Cancer Detection

Official title: Clinical Study of 18F-Labeled FAPI-04 in PET Imaging of Breast Cancer

Run by The Affiliated Hospital of Qingdao University · NCT06916338 · Data updated 2026-11-12

This study is testing a new type of PET imaging to see if it can help find breast cancer more accurately and track how tumors change during treatment.

More Breast Cancer trials

Quick facts

Study typeObservational
Ages18 Years to 75 Years
SexAll
Enrollment30 (estimated)
SponsorThe Affiliated Hospital of Qingdao University
Academic / other
Drugs / interventionschemotherapy, immunotherapy
Locations1 site (Qingdao, Shandong)
StatusRecruiting
StartedApril 11, 2025
Main results expectedDecember 2026
Study endsDecember 2027
Registry record updatedApril 29, 2025
Trial IDNCT06916338 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18-75 with confirmed breast cancer or suspected recurrence/metastasis and at least one measurable lesion.

Probably not a fit

Patients with severe infections, significant organ insufficiency, or those unable to cooperate with PET imaging may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the diagnostic accuracy of 18F-FAPI-04 PET imaging in identifying fibroblast activation protein (FAP)-rich lesions in breast cancer patients. It will monitor changes in FAP expression levels and tumor size during various therapies, including chemotherapy and immunotherapy. By providing a non-invasive alternative to traditional biopsies, this study seeks to enhance the understanding of tumor microenvironment dynamics and improve therapeutic decision-making.

Why it matters

Potential benefit: If successful, this study could lead to more accurate and non-invasive methods for diagnosing and monitoring breast cancer.

How similar studies have gone: While the use of FAP-targeted imaging is a novel approach, similar studies have shown promise in enhancing cancer detection and monitoring.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age 18-75 years old, any gender;
2. Clinically or pathologically confirmed diagnosis of breast cancer, or suspected recurrence/metastasis;
3. Presence of at least 1 measurable lesion (RECIST 1.1 criteria);
4. ECOG score 0-2 and expected survival ≥ 12 weeks;
5. Laboratory markers are met:

   Blood count: WBC ≥4.0×10⁹/L, PLT ≥100×10⁹/L, Hb ≥90 g/L Liver and kidney function: ALT/AST ≤ 2.5 × ULN, SCr ≤ 1.5 × ULN;
6. Signed informed consent.

Exclusion Criteria:

1. Major surgery or trauma within 4 weeks;
2. Severe infection, liver or kidney insufficiency;
3. History of allergies (developer components);
4. Pregnant/nursing female or not using effective contraception;
5. Inability to co-operate with PET (e.g. claustrophobia);
6. Any other situation that researchers considered it unsuitable to participate in the trial.

Where it's running

  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.